FDA Orders Enhanced Warning Labels on Opioid Pain Medications

Share this content:
FDA Orders Enhanced Warning Labels on Opioid Pain Medications
FDA Orders Enhanced Warning Labels on Opioid Pain Medications

TUESDAY, March 22, 2016 (HealthDay News) -- The U.S. Food and Drug Administration has announced that immediate-release opioid pain medications will get new boxed warnings about the dangers of misuse.

"We are at a time when the unfathomable tragedies resulting from addiction, overdose, and death has become one of the most urgent, devastating public health crises facing our country," FDA Commissioner Robert Califf, M.D., told reporters at a Tuesday news briefing. He said the agency is working with other agencies, drug makers, doctors, and patients "to prevent abuse, save lives and treat dependence while still providing patients in pain access to effective relief."

The new labeling rules are mostly aimed at immediate-release versions of opioids. According to an FDA news release, the new label requirements include: a new boxed warning on the "serious risks of misuse, abuse, addiction, overdose, and death;" a new prescribing guideline that immediate-release opioids "should be reserved for pain severe enough to require opioid treatment and for which alternative treatment options are inadequate or not tolerated;" and labeling stressing the risk of neonatal opioid withdrawal syndrome in infants born to mothers who took opioids during their pregnancy.

Besides this new labeling for immediate-release opioids, the FDA is also mandating other revised labeling for all opioids. All of these drugs will now include information on labels warning of potential harmful interactions of the drug with other medicines that can result in serotonin syndrome, the agency said. Labels will also warn of possible opioid effects on the endocrine system.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »